As immune checkpoint inhibitors (ICIs) target the dysfunctional immune system and enhance the ability of CD8+ T cells in killing tumor cells, the use of immune checkpoint inhibitors transforms the therapeutic outcome of advanced melanoma. The gene discussed is CD8A; the disease is melanoma.